Nanodispersible cannabidiol (150 mg/mL) for generalized anxiety disorder: Comparative emerging clinical evidence with first-line anxiolytics and mechanistic insights from network pharmacology and pharmacogenomics

Asian Journal of Psychiatry · Elsevier

Аннотация

Publication date: November 2026 Source: Asian Journal of Psychiatry, Volume 125 Author(s): Prasad Rao Gundugurti, Prasanna Latha Komaravalli, Amrita Chatterjee, Bharath Harohalli Byregowda, Chandrashekhar Kocherlakota, Kumar SD Kothapalli

Читать у издателя →

Похожие статьи